(Q41111239)

26 September 2017

title

Effective VCR/DEX pulse maintenance therapy in the KYCCSG ALL-02 protocol for pediatric acute lymphoblastic leukemia (English)

1 reference

26 September 2017

Yasuhiro Okamoto

1

1 reference

26 September 2017

Yuki Koga

2

1 reference

26 September 2017

Jiro Inagaki

3

1 reference

26 September 2017

Shuichi Ozono

4

1 reference

26 September 2017

Koichiro Ueda

5

1 reference

26 September 2017

Maiko Shimoura

6

1 reference

26 September 2017

Nobuyoshi Itonaga

7

1 reference

26 September 2017

Yuichi Shinkoda

8

1 reference

26 September 2017

Hiroshi Moritake

9

1 reference

26 September 2017

Yuko Nomura

10

1 reference

26 September 2017

Hideki Nakayama

11

1 reference

26 September 2017

Noriko Hotta

12

1 reference

26 September 2017

Yasufumi Hidaka

13

1 reference

26 September 2017

Hidemi Shimonodan

14

1 reference

26 September 2017

Naohiro Suga

15

1 reference

26 September 2017

Takayuki Tanabe

16

1 reference

26 September 2017

Kentaro Nakashima

17

1 reference

26 September 2017

Reiji Fukano

18

1 reference

26 September 2017

Yoshifumi Kawano

19

1 reference

26 September 2017

publication date

19 November 2015

1 reference

International Journal of Hematology

26 September 2017

published in

1 reference

26 September 2017

volume

103

1 reference

26 September 2017

issue

2

1 reference

26 September 2017

page(s)

202-209

1 reference

Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

A 50-year journey to cure childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Fatal visceral varicella-zoster virus infection without skin involvement in a child with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Treating childhood acute lymphoblastic leukemia without cranial irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institut

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Early use of allogeneic hematopoietic stem cell transplantation for infants with MLL gene-rearrangement-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-015-1910-1

Steroid-induced glaucoma in children with acute lymphoblastic leukemia: a possible complication

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26586463

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26586463

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26586463

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12185-015-1910-1

1 reference

26 September 2017

1 reference